Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis.

Chandra Sekhar YadavalliSathisha Upparahalli VenkateshaiahAlok K VermaChandrasekhar KatheraPearce S DuncanMichael VaeziRichard J PaulAnil Mishra

Published in: Cells (2024)

CRTH2 antagonist treatment is a novel therapeutic strategy for inflammatory cell-induced esophageal motility dysfunction in IL-13-induced chronic experimental EoE.

Keyphrases

oxidative stress
high glucose
diabetic rats
drug induced
biofilm formation
single cell
escherichia coli
cell therapy
combination therapy
mesenchymal stem cells
replacement therapy
candida albicans
chronic rhinosinusitis